A male case of synchronous double cancers of the breast and prostate is reported. An84-yearold male was admitted to the hospital complaining of general malaise, anorexia and weight loss. A tumor 3 cm in diameter was noted in his left breast, which was removed by mastectomy, and was diagnosed as papillotubular carcinoma. An induration of his prostate and elevated prostate specific antigen, y-seminoprotein and prostatic acid phosphatase levels were also noted. Needle biopsy of his prostate revealed adenocarcinoma. Amongthe previous 18 reported cases of this combination ofcancers, those with no prior estrogen therapy were very rare, the present case being the third ever reported. (Internal Medicine 33: 31-35, 1994) 
Introduction
Only 18 cases of primary breast cancer synchronous with primary prostatic cancer have been reported (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Among these, 15 cases developed breast cancer during the treatment of their prostatic cancer with estrogen. Recently, we diagnosed a very rare case of double primary cancers of the breast and prostate, which were not related to estrogen therapy and were detected almost simultaneously.
Case Report
An84-year-old male was referred to our hospital on March 25, 1992 because of general malaise and anorexia lasting for about three months. He had lost approximately 10 kg in the previous six months. He had diabetes mellitus from the age of 60, and was treated with 7.5 mg/day of glibenclamide. No significant family history of cancer was obtained. On physical examination, an elastic, hard mass 3 cm in diameter was noted in his left breast. He had first felt this tumor five years earlier and occasionally had experienced a bloody discharge from the nipple. There was no other abnormal finding except for pain upon percussion over his entire back. He had no dysuria. Fig. 1 ) , and administration oftamoxifen was started. Although there was no apparent metastatic lesion on plain bone X-ray films, the histological diagnosis, being combined with his back pain and high serum ALPactivity, prompted us to order 99mTc-bone scintigraphy. The examination revealed significant bony uptake, particularly on the skull and pyramid, and was felt to be consistent with wide spread bony metastases (Fig. 2) . Since tamoxifen did not relieve his back pain, we screened another possible origin(s) of bony metastases. Amongtumor markers measured at this time, prostate specific antigen (PSA), y-seminoprotein and prostatic acid phosphatase (PAP) levels were elevated (67.2, 1 1.0 and 3.8 ng/ml, respectively). Ultrasonography demonstrated prostatic hypertrophy, and a needle biopsy of the prostate was performed on April 25, giving a histologic diagnosis ofadenocarcinoma (Fig. 3) . The histologic findings of the prostate cancer appeared quite distinct from those of the breast cancer in terms of cellular size and arrangement, shape of nuclei and nucleoli, and chromatin patterns. Immunohistochemical staining of the breast cancer was negative for PSAand PAP. Therefore, this case was diagnosed as synchronous double cancers of the breast and prostate.
Tamoxifen was withdrawn due to its ineffectiveness on bony metastases, and an orchiectomy was performed on May1 1. Twodays before orchiectomy, the patient suddenly developed dyspnea and a pleural effusion was observed bilaterally (Fig. 4) . The pleural fluid was exudative, suggesting carcinomatous pleuritis, although the cytology wasnegative. As shown in Fig. 5 , following orchiectomy, the patient's dyspnea and pleural effusion improved, his ALP and LDHlevels decreased somewhat, his back pain improved, and the levels of the tumor markers decreased. The patient was discharged on June 5 , 1 992, and has had follow-up visits in our outpatient clinic. He has felt well up until his last visit in September 1993.
Discussion
As mentioned above, there have been only 1 8 reported cases (including this case) of double cancers of the breast and prostate ( Table 2 ). Cases which are not related to prior estrogen therapy are very unusual, the present patient being the third such case reported. In this case, the diagnosis of the primary prostate cancer was based on both the histologic characteristics and the elevated tumor markers such as PSA, y-seminoprotein and PAP.The patient's clinical course after orchiectomy seemsto Fig. 3 . Histologic findings of the prostate cancer obtained by needle biopsy, a) Small cells are predominant. Trabecular formation is frequently observed, and tubular structures are also found in some parts (HE stain, xlOO). b) Nuclei are irregular in shape, and nucleoli stand out. Whencompared to the histological pictures of the breast cancer, the chromatin pattern of each nucleus appears uneven (HE stain, x200). suggest that the prostate cancer was responsible for his pleuritis and multiple bone lesions. The breast tumor was strongly suspected as being a primary lesion because its histologic findings were distinct from those of the prostate cancer. In addition, immunohistochemistry of the breast tumor for PSA and PAP, performed to rule out a metastasis of prostate cancer (17), was negative. Elevated blood PSA and PAP levels and negative staining of the breast tumor tissue for PSAand PAP mayfurther confirm that the breast cancer is also a primary one.
It is not clear what the commonunderlying mechanismof
carcinogenesis is in the present patient with synchronous primary breast and prostate cancers, the former being estrogendependent and the latter testosterone-dependent. The most proclaimed hypothesis for the commonmechanism underlying the onset of double cancers of this type is the administration of estrogen, which induces gynecomastia and may provide a fertile environment for the development of mammary carcinogenesis (14, 16). In fact, as shown in Table 2 , 15 of the 1 8 reported cases of these double cancers had received estrogen treatment for their prostate cancer at the time of the diagnosis of the breast cancer. However, this hypothesis itself is still controversial (7, 20, 21 ) and in any event is not applicable to the present case. On the other hand, it is well knownthat the incidence of multiple cancers rises with age (18). Although the prevalence rate of prostate cancer is not available in Japan, the corrected mortality rate in Japan in 1990 is estimated to be 5.7/100,000 for prostate cancer and 0. 1/100,000 for male breast cancer (19). By simply multiplying these two incidences, one can roughly estimate the rate of the double cancers to be as rare as 0.6 over ten billion. However, prostate cancer is knownto be associated with an incidence of multiple cancers as high as 1 1.7% (20) or 1 3% (2 1 ). The characteristic age distribution of prostate cancer patients (older than 70 or 75 years) is postulated to be responsible for such a high incidence of multiple cancers. The actual incidence of breast cancer amongprostate cancer patients who did not receive estrogen therapy has been reported to be 1/7,000 in United Kingdom by the Birmingham Cancer Registry (14) and 1/7,000 in the United States by the Connecticut Cancer Registry (22). This incidence is not known in Japan, but the present case seems to be the first one reported in Japan.
As to the possible role of underlying diabetes mellitus and its therapeutics, diabetes mellitus is knownto occasionally reduce testosterone and androgen levels (23), and may thus promote the development of mammarycarcinogenesis. However, the actual incidence of breast and prostate cancers in patients with diabetes mellitus is not higher than in patients without diabetes mellitus (24). Chronic toxicity testing of glibenclamide, which was used in this patient to treat his diabetes mellitus, has not revealed any mutagenic side effect (25).
Taken together, the age-related rise in the incidence of multiple primary cancers, particularly in prostate cancer patients, seems to be the factor most likely responsible for the double cancers of the present case.
As to the treatment of male primary breast cancer, mastectomy and endocrine therapy with tamoxifen are the treatments of choice (16). Tamoxifen has been presumed to be effective against male breast cancer, based on the finding that the estrogen receptor positive rate is as high as 89.5% in male breast cancer (26). However, the efficacy of this drug on prostatic cancer has been questioned by some investigators. Glick et al (27) have reported that the partial response rate and disease stabilization rate in a phase II trial oftamoxifen were as low as 7 and 20%, respectively, for patients with metastatic prostate cancer. Administration of LH-RHantagonist is regarded to be the first choice amongendocrinologic treatments for prostate cancer, but the agent may raise the estrogen level transiently and induce gynecomasthia in approximately 2% of patients who receive the drug (phase III clinical trial data from ICI Pharma Co., Ltd. Osaka, Japan). Although we did not know what definite effect this possible transient surge of estrogen may excert on his breast cancer, we favored orchiectomy which removesthe major source of both testosterone and estrogen in males. Thus, the present patient underwent both mastectomy and orchiectomy. The significant improvement observed in his clinical course after the operations support our management of this patient.
